티앤알바이오팹

246710KOSDAQ기초 의약물질 제조업

55.3 / 100

Reference Date: 2026-07-24

Financial Score13.0 / 40

News Sentiment21.3 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Surged 20.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

T&N Biofabrication focuses on regenerative medicine, bio-surgical solutions, and cosmetics, leveraging its 3D bioprinting systems, bioinks, and biodegradable scaffolds. The company is developing 3D organoids and cell therapies through long-term R&D while also advancing short-term revenue streams via bio-surgical solutions.

Number of Employees

82people

Average Salary

51.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 25.444.0Point

PBR

4.81Industry Average 1.260.0Point

3.8x industry avg (risky)

ROE

-147.79Industry Average -6.033.5Point

24.5x industry avg (excellent)

Debt Ratio

228.72Industry Average 6.620.0Point

34.5x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲223.5% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲13.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -71.2% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
티앤알바이오팹, 상반기 매출 183억…전년 동기보다 46% 증가
티앤알바이오팹의 상반기 매출이 전년 동기 대비 46% 증가하며 성장성이 입증되었다.
Positive
티앤알바이오팹, 심장질환 치료용 고순도 심근세포 정제 기술 특허 확.....
티앤알바이오팹이 심장질환 치료에 특화된 고순도 심근세포 정제 기술 특허를 확보하여 기술적 우위를 강화했다.

Detailed Momentum

52-week position3.0Point

52w lower range (34%)

Current 2,330Won52-week high 4,53552-week low 1,194

1-month return6.0Point

1m +20.48% (strong rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral[기재정정]주식등의대량보유상황보고서(일반)2026-07-14
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-14
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-14
Neutral연결재무제표기준영업(잠정)실적(공정공시)2026-07-14
Neutral주식등의대량보유상황보고서(일반)2026-07-13